• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Veradermics Incorporated

    5/7/26 4:41:17 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MANE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Veradermics, Incorporated

    (Name of Issuer)


    Common Stock, par value $0.00001 per share (the "Shares")

    (Title of Class of Securities)




    922967104

    (CUSIP Number)
    04/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,870,775.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,870,775.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,870,775.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 41,183,254 Shares outstanding as of May 1, 2026 (according to the issuer's prospectus as filed with the Securities and Exchange Commission on April 30, 2026). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on May 7, 2026.


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,870,775.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,870,775.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,870,775.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,870,775.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,870,775.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,870,775.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    17.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    17.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    17.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    17.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    17.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    17.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    17.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    17.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    17.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    922967104


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,870,792.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,870,792.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,870,792.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Veradermics, Incorporated
    (b)Address of issuer's principal executive offices:

    470 James Street, New Haven, CT 06513
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of the Reporting Persons is 830 Brickell Plaza, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share (the "Shares")
    (e)CUSIP Number(s):

    922967104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,870,775 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 17 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 17 Shares. 4. Mr. Griffin may be deemed to beneficially own 1,870,792 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 4.5% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 4.5% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,870,775 2. Citadel Securities LLC: 17 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 17 4. Mr. Griffin: 1,870,792

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,870,775 2. Citadel Securities LLC: 17 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 17 4. Mr. Griffin: 1,870,792

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Citadel Securities LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Citadel Securities Group LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Citadel Securities GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/07/2026
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:05/07/2026

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $MANE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MANE

    DatePrice TargetRatingAnalyst
    7/15/2026$170.00Buy
    B. Riley Securities
    6/2/2026$136.00Buy
    Needham
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$85.00Buy
    Citigroup
    3/2/2026$75.00Buy
    Jefferies
    3/2/2026$75.00Outperform
    Leerink Partners
    More analyst ratings

    $MANE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Suvretta Capital Management, Llc

    4 - Veradermics, Inc (0001827635) (Issuer)

    5/5/26 9:37:59 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Seven Fleet Capital Management Lp claimed ownership of 80,000 shares (SEC Form 3)

    3 - Veradermics, Inc (0001827635) (Issuer)

    5/5/26 7:42:22 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Childs John W bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

    4/A - Veradermics, Inc (0001827635) (Issuer)

    2/27/26 4:44:06 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

    4/A - Veradermics, Inc (0001827635) (Issuer)

    2/27/26 4:44:06 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/9/26 6:28:51 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/5/26 7:04:25 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

    Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral min

    7/17/26 7:30:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with

    7/15/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

    Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab

    7/14/26 6:54:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Veradermics with a new price target

    B. Riley Securities initiated coverage of Veradermics with a rating of Buy and set a new price target of $170.00

    7/15/26 8:53:05 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Veradermics with a new price target

    Needham initiated coverage of Veradermics with a rating of Buy and set a new price target of $136.00

    6/2/26 8:39:26 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Veradermics

    Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight

    3/2/26 9:08:57 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Financials

    Live finance-specific insights

    View All

    Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with

    7/15/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

    Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab

    7/14/26 6:54:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient

    4/27/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    SEC Filings

    View All

    Veradermics Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Veradermics, Inc (0001827635) (Filer)

    7/15/26 8:54:36 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Veradermics Incorporated

    SCHEDULE 13G/A - Veradermics, Inc (0001827635) (Subject)

    5/15/26 5:48:36 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Veradermics Incorporated

    D - Veradermics, Inc (0001827635) (Filer)

    5/15/26 2:02:28 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care